407 related articles for article (PubMed ID: 32296911)
1. Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma.
Nijland M; Bakker M; Meijer K; Plattel W
Ann Hematol; 2020 Dec; 99(12):2947-2948. PubMed ID: 32296911
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
Gao Y; Xie Y; Liu L; Xue H; Hou M; Zhang M; Zhou Z; Guo P; Yao H; Shao Z; Xie X; Zhu J
Minerva Med; 2021 Apr; 112(2):310-312. PubMed ID: 31317691
[No Abstract] [Full Text] [Related]
3. Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
Djebbari F; Browning JA; Stanton L; Booth S; Hildyard C; Willan J; Bosworth J; Vora SM; Hatton CSR; Collins GP; Eyre TA
Br J Haematol; 2019 Sep; 186(6):e191-e195. PubMed ID: 31222716
[No Abstract] [Full Text] [Related]
4. Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma.
Ureshino H; Ando T; Kojima K; Itamura H; Jinnai S; Doi K; Ohshima K; Kurogi K; Miyahara M; Kimura S
Intern Med; 2015; 54(24):3205-8. PubMed ID: 26666614
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
6. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy.
Yokoo M; Kojima K; Sano H; Kai K; Arakawa F; Ohshima K; Matsunaga T; Kimura S
Ann Hematol; 2019 Jun; 98(6):1501-1503. PubMed ID: 30406822
[No Abstract] [Full Text] [Related]
7. Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma.
Matsuo T; Tanaka T; Yano T
J Clin Exp Hematop; 2018 Dec; 58(4):180-183. PubMed ID: 30416173
[No Abstract] [Full Text] [Related]
8. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
9. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
10. Promising new combination therapy for non-GCB DLBCL.
Gourd E
Lancet Oncol; 2019 May; 20(5):e245. PubMed ID: 30930026
[No Abstract] [Full Text] [Related]
11. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ; de Nully Brown P; van der Holt B; D'Amore FA; Koene HR; de Jongh E; Fijnheer R; van Esser JW; Böhmer LH; Pruijt JF; Verhoef GE; Hoogendoorn M; Bilgin MY; Nijland M; van der Burg-de Graauw NC; Oosterveld M; Jie KG; Larsen TS; van der Poel MW; Leijs MB; Silbermann MH; van Marwijk Kooy M; Beeker A; Kersten MJ; Doorduijn JK; Tick LW; Brouwer RE; Lam KH; Burggraaff CN; de Keizer B; Arens AI; de Jong D; Hoekstra OS; Zijlstra-Baalbergen JM
J Clin Oncol; 2020 Oct; 38(29):3377-3387. PubMed ID: 32730183
[TBL] [Abstract][Full Text] [Related]
12. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
Kari E; Teppo HR; Haapasaari KM; Kuusisto MEL; Lemma A; Karihtala P; Pirinen R; Soini Y; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
[TBL] [Abstract][Full Text] [Related]
15. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
[No Abstract] [Full Text] [Related]
16. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]